YU24004A - Interleukin-12 kao adjuvant veterinarske vakcine - Google Patents

Interleukin-12 kao adjuvant veterinarske vakcine

Info

Publication number
YU24004A
YU24004A YU24004A YUP24004A YU24004A YU 24004 A YU24004 A YU 24004A YU 24004 A YU24004 A YU 24004A YU P24004 A YUP24004 A YU P24004A YU 24004 A YU24004 A YU 24004A
Authority
YU
Yugoslavia
Prior art keywords
immunogenicity
enhancing
composition
immunoadjuvant
immunomodulator
Prior art date
Application number
YU24004A
Other languages
English (en)
Inventor
Anne Rosenblum
Hsien-Jue Chu
Original Assignee
Wyeth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth filed Critical Wyeth
Publication of YU24004A publication Critical patent/YU24004A/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Opisan je preprat za jačanje imunogeniciteta veterinarske vakcine koji sadrži farmakološki efikasnu količinu imunomodulatora i imunoađuvanta. Pored toga, opisan je preparat vakcine koji sadrži količinu koja efikasno imunizuje antigen, imunomodulator, imunoađuvant i farmaceutski prihvatljiv nosač. Ovaj preparat može opciono da sadrži konvencionalne sekundarne ađuvante ili prezervative. Opisuje se još jedinstven postupak jačanja ili ubrzavanja imunogeniciteta slabog, imunosupresivnog ili marginalno sigurnog antigena, ordiniranjem ptičjoj ili sisarskoj vrsti farmakološki efikasne količine gore-pomenutog preparata za jačanje imunogeniciteta, ili imuno efikasna količina gore pomenutog preparata vakcine.[This disclosure describes a composition for enhancing the immunogenicity of a veterinary vaccine that comprises a pharmacologically effective amount of an immunomodulator and an immunoadjuvant. Additionally, the disclosure describes a vaccine composition comprising an effective immunizing amount of an antigen, an immunomodulator, an immunoadjuvant and a pharmaceutically acceptable carrier. The compositions may optionally contain conventional, secondary adjuvants or preservatives. The disclosure further describes a unique method for enhancing or accelerating the immunogenicity of weak, immunosuppressive or marginally safe antigens by administering to an avian or mammalian species a pharmacologically effective amount of the aforesaid immunogenicity enhancing composition or an effective immunizing amount of the aforesaid vaccine composition.
YU24004A 2001-09-17 2002-09-13 Interleukin-12 kao adjuvant veterinarske vakcine YU24004A (sh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32284001P 2001-09-17 2001-09-17
US10/243,075 US20030129161A1 (en) 2001-09-17 2002-09-12 Interleukin-12 as a veterinary vaccine adjuvant

Publications (1)

Publication Number Publication Date
YU24004A true YU24004A (sh) 2006-08-17

Family

ID=26935571

Family Applications (1)

Application Number Title Priority Date Filing Date
YU24004A YU24004A (sh) 2001-09-17 2002-09-13 Interleukin-12 kao adjuvant veterinarske vakcine

Country Status (14)

Country Link
US (2) US20030129161A1 (sh)
EP (1) EP1427349A4 (sh)
JP (1) JP2005520786A (sh)
KR (1) KR20040044942A (sh)
CN (1) CN1555271A (sh)
BR (1) BR0212556A (sh)
CA (1) CA2457563A1 (sh)
HR (1) HRP20040282A2 (sh)
HU (1) HUP0500238A3 (sh)
MX (1) MXPA04002490A (sh)
NZ (1) NZ531526A (sh)
PL (1) PL374123A1 (sh)
WO (1) WO2003024354A2 (sh)
YU (1) YU24004A (sh)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7347996B1 (en) * 2002-06-26 2008-03-25 Intevert International B.V. Avian cytokines, such as IL-12, comprising a p40 and/or p35 subunit and vaccines
US20050089533A1 (en) * 2003-01-29 2005-04-28 Joseph Frantz Canine vaccines against Bordetella bronchiseptica
CA2548210A1 (en) * 2003-12-05 2005-08-18 Becton, Dickinson And Company Methods of enhancing immune response in the intradermal compartment and compounds useful in the methods
US20050202046A1 (en) * 2004-03-11 2005-09-15 Wyeth Canine vaccine for protection against ehrlichiosis
CN100425288C (zh) * 2005-01-28 2008-10-15 北京金迪克生物技术研究所 鼻腔喷雾型流感病毒灭活疫苗及其制备方法
KR100517114B1 (ko) * 2005-02-25 2005-09-27 주식회사 바이오리더스 폴리감마글루탐산을 함유하는 면역보강제 조성물
EP1928492B1 (en) 2005-09-01 2011-02-23 Celgene Corporation Immunological uses of immunodulatory compounds for vaccine and anti-infections disease therapy
US7682619B2 (en) * 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
US20100028379A1 (en) 2006-12-27 2010-02-04 Pfizer, Inc Methods of vaccine administration
KR100836745B1 (ko) * 2007-01-31 2008-06-10 (주)두비엘 Ｈｂｖ 백신 및 그의 제조 방법
CL2008001806A1 (es) 2007-06-20 2008-09-05 Wyeth Corp Composicion de vacuna en emulsion agua en aceite que comprende un antigeno y un adyuvante en la fase acuosa; y metodo de elaboracion.
CA2685533C (en) * 2007-06-22 2019-07-02 University Of Guelph Vaccine against clostridium perfringens
FR2922767B1 (fr) * 2007-10-24 2009-12-18 Seppic Sa Procede de preparation d'une composition vaccinale comprenant au moins un antigene et au moins un adjuvant.
KR101225304B1 (ko) 2007-11-06 2013-01-22 와이어쓰 엘엘씨 마이코플라스마 하이오뉴모니아에 비독성 항원보강된 살아있는 백신
US8273122B2 (en) 2008-06-23 2012-09-25 Abbott Medical Optics Inc. Pre-loaded IOL insertion system
CN105203755B (zh) * 2009-11-20 2018-01-05 爱贝斯股份有限公司 用于检测埃里希体属抗体的肽、装置和方法
WO2011146574A1 (en) * 2010-05-18 2011-11-24 Neumedicines, Inc. Il-12 formulations for enhancing hematopoiesis
CN102908613A (zh) * 2011-08-04 2013-02-06 广州格拉姆生物科技有限公司 一种猪用免疫增强剂il-12b(p40)及其制备方法
US9651546B2 (en) 2012-10-11 2017-05-16 Abaxis, Inc. Peptides, devices, and methods for the detection of ehrlichia antibodies
CN103028114A (zh) * 2012-12-28 2013-04-10 贵州大学 一种核酸疫苗、核酸疫苗免疫佐剂及制备方法
US9442112B2 (en) 2014-04-04 2016-09-13 Abaxis, Inc. Compositions and methods for identifying Ehrlichia species
CN104857511B (zh) * 2015-02-13 2018-03-30 浙江大学 含人参皂甙的疫苗稀释剂
KR20200060540A (ko) * 2015-09-09 2020-05-29 칭화 유니버시티 고-효율 백신 아쥬반트로서 메발로네이트 경로 억제제

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567042A (en) * 1983-06-15 1986-01-28 American Home Products Corporation Inactivated canine coronavirus vaccine
US5047238A (en) * 1983-06-15 1991-09-10 American Home Products Corporation Adjuvants for vaccines
US5643565A (en) * 1985-09-20 1997-07-01 Chiron Corporation Human IL-2 as a vaccine adjuvant
US5503841A (en) * 1985-09-20 1996-04-02 Cetus Oncology Corporation Human IL-2 as a vaccine adjuvant
US5266311A (en) * 1987-05-28 1993-11-30 Immunex Corporation Bovine interleukin-1α
US4894333A (en) * 1987-05-28 1990-01-16 Immunex Corporation Bovine interleukin-1α
US5106733A (en) * 1987-06-25 1992-04-21 Immunex Corporation Bovine granulocyte-macrophage colony stimulating factor
US5242686A (en) * 1990-11-07 1993-09-07 American Home Products Corporation Feline vaccine compositions and method for preventing chlamydia infections or diseases using the same
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5571515A (en) * 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
KR100374434B1 (ko) * 1994-05-10 2003-06-09 와이어쓰 변형된소호흡관련합포체바이러스(brsv)생백신조성물
JP3939752B2 (ja) * 1994-10-05 2007-07-04 バンダービルト ユニバーシティー パラミクソウイルスワクチン用アジュバントとしてのインターロイキン−１２
US5674483A (en) * 1995-01-31 1997-10-07 National Jewish Medical And Research Center Treatment for diseases involving inflammation
US5665347A (en) * 1995-02-02 1997-09-09 Genetics Institute IL-12 inhibition of B1 cell activity
AU695129B2 (en) * 1995-02-06 1998-08-06 Genetics Institute, Llc Formulations for IL-12
US5853714A (en) * 1995-03-27 1998-12-29 Genetics Institute, Inc. Method for purification of IL-12
US5820869A (en) * 1995-06-07 1998-10-13 American Home Products Corporation Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection
US5972350A (en) * 1996-05-06 1999-10-26 Bayer Corporation Feline vaccines containing Chlamydia psittaci and method for making the same
AU724743B2 (en) * 1996-05-31 2000-09-28 Genetics Institute, Llc IL-12 as an adjuvant for Bordetella Pertussis vaccines
GB9712347D0 (en) * 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
CA2243730C (en) * 1997-07-29 2009-12-22 Akzo Nobel N.V. Streptococcus equi vaccine
IL137810A0 (en) * 1998-02-12 2001-10-31 American Cyanamid Co Vaccines comprising interleukin-12 and respiratory syncytial viral antigens
US5985264A (en) * 1998-03-05 1999-11-16 The Medical College Of Ohio IL-12 Stimulation of Neonatal immunity
US6375944B1 (en) * 1998-09-25 2002-04-23 The Wistar Institute Of Anatomy And Biology Methods and compositions for enhancing the immunostimulatory effect of interleukin-12
US6458942B1 (en) * 1998-11-30 2002-10-01 Research Development Foundation 28-kDa immunoreactive protein gene of Ehrlichia canis and uses thereof
AU6683400A (en) * 1999-07-08 2001-01-30 Mologen Forschungs-, Entwicklungs- Und Vertriebs Gmbh Vaccine against lentiviral infections, such as the feline immune deficiency virus of the cat

Also Published As

Publication number Publication date
HUP0500238A2 (hu) 2005-05-30
HRP20040282A2 (en) 2004-08-31
WO2003024354A3 (en) 2004-02-05
US20030129161A1 (en) 2003-07-10
WO2003024354A2 (en) 2003-03-27
NZ531526A (en) 2007-05-31
EP1427349A2 (en) 2004-06-16
CN1555271A (zh) 2004-12-15
BR0212556A (pt) 2007-04-17
MXPA04002490A (es) 2004-05-31
CA2457563A1 (en) 2003-03-27
HUP0500238A3 (en) 2009-01-28
EP1427349A4 (en) 2006-01-11
US20080003201A1 (en) 2008-01-03
KR20040044942A (ko) 2004-05-31
JP2005520786A (ja) 2005-07-14
PL374123A1 (en) 2005-10-03

Similar Documents

Publication Publication Date Title
YU24004A (sh) Interleukin-12 kao adjuvant veterinarske vakcine
MXPA01007760A (es) Compuesto adyuvante inmunologico.
WO2003011223A3 (en) Immunomodulatory compounds and methods of use thereof
BR9912177A (pt) Epìtopos de célula auxiliar t artificiais como imunoestimuladores para imunógenos de peptìdeo sintéticos
HK1072264A1 (en) Synthetic peptide vaccines for hiv: the cbd epitope as an effective immunogen to elicit broadly neutralizing antibodies against hiv
HK1044484A1 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide.
PT2364724E (pt) Composição de vacina compreendendo um adjuvante de saponina
HK1038507A1 (en) Influenza virus vaccine composition
GB0025577D0 (en) Vaccine
IL150602A (en) Proteosome influenza vaccine, method for preparing such and use thereof
WO2002034119A3 (en) Vaccine immunotherapy for immune suppressed patients
YU8004A (sh) Vakcina protiv bolesti zapadnog nila
WO2001097841A3 (en) Qs-21 and il-12 as an adjuvant combination
AU2003212170A1 (en) Chemotherapeutic agents as anti-cancer vaccine adjuvants and therapeutic methods thereof
WO2003083083A3 (en) Methods of using flt3-ligand in immunization protocols
AU3478393A (en) Vaccine containing acemannan as an adjuvant
CA2330313A1 (en) Immunization against and treatment for infection by h.pylori
MY141983A (en) Hepatitis b virus surface antigen as a mucosal immunoenhancer, resulting formulations
WO2002004497A3 (en) Multiple antigenic peptides immunogenic against streptococcus pneumoniae
PL341541A1 (en) Isolated strains of staphyloccoccus aureus and vaccines prepared of them
WO2003040163A3 (en) Immunomodulating saponins, a method for their preparation and their use for vaccines